Scholarlink

Introduction <p>Diffuse large B-cell lymphoma (DLBCL) of the hard palate is a rare extranodal manifestation of non-Hodgkin’s lymphoma (NHL), presenting diagnostic and therapeutic challenges due to its uncommon location and clinical overlap with other oral malignancies.</p> Case Presentation <p>We report a case of a 32-year-old female with a 5x3 cm smooth palatal swelling, initially suspected to be a minor salivary gland tumor. Contrast-enhanced computed tomography (CECT) revealed a lesion confined to the palate with intact bone, and core needle biopsy confirmed DLBCL with CD20 positivity and negativity for pancytokeratin and CD3. FDG-PET scanning showed no systemic disease, and the patient achieved complete remission after six cycles of R-CHOP chemotherapy followed by one year of maintenance rituximab, remaining disease-free five years post-therapy.</p> Conclusions <p>A literature review highlights DLBCL’s rarity in the palate, its variable presentation as ulcerative or smooth masses, and the critical role of immunohistochemistry and imaging in diagnosis. Molecular subtyping of NHL and emerging therapies, such as immune checkpoint inhibitors and antibody-drug conjugates, offer promise for personalized treatment. This case underscores the importance of a multidisciplinary approach integrating immunohistochemistry, FDG PET scan and anti CD20 antibody therapy to achieve favorable outcomes in rare palatal DLBCL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolated Primary Diffuse Large B-cell Lymphoma of the Hard Palate: A Case Report

  • 期刊论文

  • 发表日期：

    2025年11月29日

查看全文
  • Dency Hansalia,
  • Akshay Kantha,
  • Manoj Pandey

摘要

Introduction

Diffuse large B-cell lymphoma (DLBCL) of the hard palate is a rare extranodal manifestation of non-Hodgkin’s lymphoma (NHL), presenting diagnostic and therapeutic challenges due to its uncommon location and clinical overlap with other oral malignancies.

Case Presentation

We report a case of a 32-year-old female with a 5x3 cm smooth palatal swelling, initially suspected to be a minor salivary gland tumor. Contrast-enhanced computed tomography (CECT) revealed a lesion confined to the palate with intact bone, and core needle biopsy confirmed DLBCL with CD20 positivity and negativity for pancytokeratin and CD3. FDG-PET scanning showed no systemic disease, and the patient achieved complete remission after six cycles of R-CHOP chemotherapy followed by one year of maintenance rituximab, remaining disease-free five years post-therapy.

Conclusions

A literature review highlights DLBCL’s rarity in the palate, its variable presentation as ulcerative or smooth masses, and the critical role of immunohistochemistry and imaging in diagnosis. Molecular subtyping of NHL and emerging therapies, such as immune checkpoint inhibitors and antibody-drug conjugates, offer promise for personalized treatment. This case underscores the importance of a multidisciplinary approach integrating immunohistochemistry, FDG PET scan and anti CD20 antibody therapy to achieve favorable outcomes in rare palatal DLBCL.